To include your compound in the COVID-19 Resource Center, submit it here.

Spero's SPR741 well tolerated in Phase I

Spero Therapeutics LLC (Cambridge, Mass.) reported data from a Phase I trial in 96 healthy

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE